.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recurrent vulvovaginal candidiasis (RVVC) presents a persistent challenge for clinicians and patients globally. Standard antifungal treatments often show reduced efficacy in recurrent cases, primarily due to the formation of fungal biofilms. Consequently, medical educators are exploring therapeutic alternatives such as probiotics. However, recent scientific focus has shifted toward postbiotics for RVVC treatment. Postbiotics include cellular components and metabolites derived from probiotics that provide health benefits without the risks associated with live microorganisms.
A recent study evaluated the anti-biofilm activity of cell-free supernatants (CFSs) derived from specific probiotic strains. Researchers tested CFSs from Lacticaseibacillus rhamnosus DM-UFMG 63, Bifidobacterium longum 5,1A, and Lactobacillus acidophilus NCFM SD 5221. They examined these against 40 Candida spp. isolates from patients suffering from RVVC. The results were significant. At a protein concentration of approximately 200μg/mL, these supernatants inhibited biofilm formation by nearly 50%.
This inhibition is vital because biofilms act as physical barriers. They protect fungal cells from the host immune system and antifungal agents. Therefore, disrupting this structure is a primary goal in managing recurrent infections. Using postbiotics for RVVC treatment offers a targeted approach to destabilizing these resilient fungal communities.
Beyond physical inhibition, postbiotics influence Candida at the genetic level. The study utilized qPCR to measure the expression of genes associated with biofilm development. Specifically, researchers observed a significant downregulation of the HWP1 and ALS3 genes in Candida albicans isolates. These genes play critical roles in adhesion and the structural integrity of the biofilm matrix. By suppressing these virulence factors, postbiotics effectively reduce the pathogenic potential of the fungi.
Furthermore, this research suggests that postbiotics could serve as a safer alternative to live probiotics. They eliminate concerns regarding microbial translocation or infections in immunocompromised individuals. As the medical community seeks more robust solutions for RVVC, postbiotics emerge as a promising pharmacological candidate.
Postbiotics are non-viable bacterial products or metabolic byproducts from probiotics, such as enzymes, peptides, and organic acids, that provide physiological benefits to the host.
They work by inhibiting the formation of biofilms and downregulating specific genes like HWP1 and ALS3, which are essential for the fungus to adhere to surfaces and grow into resistant structures.
Yes, postbiotics are generally considered safer because they do not contain live microorganisms, which reduces the risk of unintended infections or bacterial translocation, especially in sensitive patient populations.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Consuegra-Asprilla JM et al. Effect of postbiotics on biofilm formation and gene expression in Candida spp. isolates from patients with recurrent vulvovaginal candidiasis. Med Mycol. 2026 Jun 11. doi: undefined. PMID: 42275129.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new study explores postbiotics from probiotic strains like L. acidophilus as an alternative for recurrent vulvovaginal candidiasis (RVVC). Results show a 50% inhibition in Candida biofilm formation and significant downregulation of virulence genes (HWP1 and ALS3), offering a promising non-living therapy.
last month
Researchers at SGPGIMS Lucknow have isolated and cultured human heart valve interstitial cells from donor tissues. This milestone advances understanding of rheumatic heart disease pathways like TGF-beta/SMAD3 and ERK1/2, laying the foundation for tissue-engineered heart valves and drug testing.
Today
Johnson & Johnson announced a $5.5 billion settlement to resolve nearly 69,000 lawsuits alleging its talc-based baby powder caused ovarian cancer. This comprehensive deal covers 99.75% of active claims. Read about the legal strategy, scientific evidence on talc exposure, and clinical counseling for patients.
Today
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
4 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
4 days back
Deepinder Goyal's healthtech startup Temple is raising capital at a $500 million valuation and pricing its temporal wearable at Rs 80,000. Worn on the side of the forehead, the device tracks microvascular blood flow and real-time Entropy to monitor physiological stress, metabolic expenditure, and recovery.
Today
